Video Watch
A growing library of physician explainers, research interviews, and reporting that shape the public peptide conversation. Videos are discovery signals—not evidence or treatment guidance.
Editor pick
GHK-Cu & skin
A board-certified dermatologist separates topical copper-peptide evidence from the newer injectable GHK-Cu trend using a clear, product-specific visual explainer.
82K views · 536 comments · 2.7M subscribers · checked Jul 10, 2026
Use as a public-claims map; verify efficacy, administration, and safety claims against primary literature and regulatory sources.
Editor pick
Recovery peptides
Two physicians use a literal BPC-157 vial and an evidence-versus-hype frame to address the compound readers most often associate with injury recovery.
169K views · 919 comments · 1.3M subscribers · checked Jul 10, 2026
Treat the discussion as expert media commentary; use human studies and regulatory records for factual conclusions.
Editor pick
Recovery peptides
A high-production interview built around unknown risks gives the video rail a broader safety lens beyond single-compound benefit claims.
8.5K views · 88 comments · 140K subscribers · checked Jul 10, 2026
Use to identify safety questions and recurring claims; cite primary toxicology, clinical, and regulatory sources on guide pages.
Editor pick
Retatrutide
A concise news report connects the nickname 'reta' to the real investigational drug and the safety questions around online availability.
7.2K views · 30 comments · 559K subscribers · checked Jul 10, 2026
Use as a reporting lead; verify legal status, trial status, and enforcement details with FDA and primary records.
Retatrutide
Long-form doctor-led retatrutide discussion with monitoring, diet, exercise, and supplement chapters that may shape reader search behavior.
13K views · 57 comments · 54K subscribers · checked Jun 30, 2026
Track as a media signal; do not convert the episode into treatment, dosing, or purchasing guidance.
Retatrutide
High-view retatrutide explainer using strong outcome language; useful for identifying claims that need careful source separation.
615K views · 1.2K comments · 224K subscribers · checked Jun 30, 2026
Check claims against primary regulatory and trial sources before any page update.
Peptide science
Large-audience peptide safety conversation that can influence mainstream questions and category-level search demand.
416K views · 1K comments · 7.6M subscribers · checked Jun 30, 2026
Use only to identify questions and themes; cite primary sources for factual claims.
Retatrutide
Another long-form retatrutide masterclass format that helps compare recurring claims and audience questions.
200K views · 665 comments · 390K subscribers · checked Jun 30, 2026
Treat as a discovery source for public questions, not as evidence.
GLP-1 drugs
Medical doctor explainer on tirzepatide mechanism and clinical context.
315K views · not shown comments · not shown subscribers · checked Jul 1, 2026
Track as expert media signal. Verify any specific clinical claims against primary sources.
GLP-1 drugs
High-view video discussing alternatives to Mounjaro, indicating public interest in non-prescription options.
482K views · not shown comments · not shown subscribers · checked Jul 1, 2026
Track alternative-seeking behavior. Do not convert into sourcing or purchasing guidance.
GLP-1 drugs
Huberman Lab discussion on GLP-1 mechanism with neuroscience perspective.
204K views · not shown comments · not shown subscribers · checked Jul 1, 2026
Track as expert media. Verify mechanistic claims against primary literature.
GLP-1 drugs
Massive-view (3.5M+) mainstream explainer on Ozempic/semaglutide. Key signal for public understanding and claim patterns.
3.6M views · not shown comments · not shown subscribers · checked Jul 1, 2026
Track for mainstream framing of GLP-1 drugs. High influence on public perception.
GLP-1 drugs
High-view (2.9M+) anatomy-focused explainer on physiological effects of GLP-1 drugs.
3M views · not shown comments · not shown subscribers · checked Jul 1, 2026
Track for physiological claims. Verify anatomical and mechanistic assertions against primary sources.
GLP-1 drugs
Mainstream 60 Minutes coverage providing clinical and regulatory context for Wegovy/Ozempic.
647K views · not shown comments · not shown subscribers · checked Jul 1, 2026
Track for regulatory and clinical framing in mainstream media.
No videos match that search yet.